Rydex Biotechnology C
9601 Blackwell Road Suite 500 Rockville MD 20850
Map
Phone: 800-820-0888
| Category: | Specialty-Health | | Fund Family: | Rydex | | Net Assets: | 7.43M | | Year-to-Date Return: | 7.81% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 30-Mar-01 |
|
Michael P. Byrum
Lead Manager since
01-Apr-98 | | | Byrum has been associated with Rydex Investments since it was founded in 1993. He was named the chief operating officer of Rydex Investments in 2003 and has served as chief investment officer of Rydex Investments since 2000. Ryrum holds the Charted Financial Analyst designation. |
| Min Initial Investment: | $2,500 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $0 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $0 |
|
| |
| The investment seeks capital appreciation. The fund primarily invests in equity securities issued by biotechnology companies that are traded in the United States, as well as in futures and options contracts. Biotechnology companies include those engaged in the research, development, and manufacture of various biotechnological and biomedical products. It is nondiversified. |
| Last Dividend
| N/A | | Last Cap Gain
| N/A | | Annual Holdings Turnover
| 193.00% | | Average for Category:
| 101.64% |
|
| Expense | RYCFX | Category
Avg | | Total Expense Ratio: | 2.38%
| 1.67% | | Max 12b1 Fee: | 1.00%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.30% | | Max Deferred Sales Load: | 1.00%
| 2.94% | | 3 Yr Expense Projection*: |
$742 | $722 | | 5 Yr Expense Projection*: |
$1,270 | $1,074 | | 10 Yr Expense Projection*: |
$2,716 | $2,092 |
|
|
1.49% Nasdaq 
0.27%
Profile
